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Background: Asthma is a prevalent and potentially life-threatening disease associated with exacerbation and 
costly hospital admissions. The coagulation cascade is up-regulated in severe asthma and increased fibrino-
genesis in the airway may precede exacerbation in moderate asthma. 
Objective: A longitudinal prospective study to test the hypothesis that levels of urinary fibrinopeptide A (FP-A), a 
marker of coagulation, increase prior to an exacerbation of asthma. 
Methods: 24 non-smoking participants with moderate to severe asthma were recruited and followed to exacer-
bation and to recovery for up to 8 weeks afterwards. Baseline measurements included spirometry, full blood 
count, atopic status and plasma markers of coagulation. Participants provided daily Peak Expiratory Flow (PEF) 
readings and three urine samples per week for analysis of FP-A, a specific marker of activation of coagulation. A 
novel method to concentrate urinary FP-A for immunodetection and quantification was developed. Participants 
were followed up until exacerbation, when baseline measurements were repeated, and monthly thereafter for 2 
months or to recovery. 
Measurements and main findings: 17 participants exacerbated during the study. Significantly increased concen-
trations of plasma D-dimer (0.25(0.2–0.42) vs 0.21(0.12–0.29) μg FEU/ml, p  0.02) were found at exacerbation. 
A peak in urinary FP-A concentration was detected on average 4.2  2 days prior to exacerbation and was 
significantly (p < 0.05) higher than at exacerbation or 7 days later. Urinary FP-A concentrations correlated 
positively with time to recovery and negatively (p < 0.01) with IgE concentration. 
Conclusion: FP-A is detectable in urine several days before the onset of an asthma exacerbation indicating 
disordered coagulation preceding asthma exacerbations.   
1. Introduction 
Asthma is a global health problem affecting 300 million people 
worldwide [1] and leading to 397,000 deaths per year [2]. Exacerba-
tions account for the majority of mortality and costs attributable to 
asthma [3–5], and are one of the main reasons for hospitalisation. Viral 
respiratory tract infection and allergy are major risk factors for exacer-
bation of asthma [6] and uncontrolled Type 2 airway inflammation in-
creases the risk of exacerbation in exacerbation prone patients [7]. 
Inflammation is closely integrated with innate immune defences and 
coagulation systems [8,9]. We have previously demonstrated that severe 
asthma requiring high dose inhaled corticosteroid therapy is associated 
with a pro-fibrinogenic, anti-fibrinolytic environment in the airways 
[10] and fibrin formation in the airways of a patient with fatal asthma 
has been described [11]. Both viral infection [12] and allergen exposure 
[13], major triggers of exacerbations, have been shown to activate the 
intrapulmonary coagulation cascade. The balance of the systemic 
coagulation cascade is affected in both non-allergic [14] and allergic 
asthma [15], with evidence of further increased systemic fibrin for-
mation/decreased fibrinolysis on exacerbation in adults [15] and chil-
dren [16]. 
Intrapulmonary fibrin formation is proposed to induce airway 
closure by neutralising surfactant and increasing the surface tension of 
airway surface liquids [11]. In addition, fibrinopeptides A and B, which 
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are released during thrombin-mediated conversion of fibrinogen to 
fibrin, were reported to decrease lung compliance and ventilatory 
conductance and decrease pulmonary blood flow [17], to activate 
neutrophil elastase release and mast cell histamine release [18] and to 
have fibroblast mitogenic activity [19] important in airway remodelling. 
However, little is known of the risk of exacerbations in relation to 
markers of coagulation in urine or plasma. Therefore, in this study we 
sought to prospectively assess changes from baseline in plasma markers 
of coagulation at exacerbation, and concentration of FP-A in urine 
before, during and after exacerbation of asthma. 
2. Methods 
2.1. Study population and assessments 
Study participants aged 18–70 years were recruited from the severe 
asthma clinic at Portsmouth Hospitals NHS Trust (PHT), had a physician 
diagnosis of asthma for at least 12 months, at least one exacerbation in 
the previous 12 months, were exacerbation free for the preceding 4 
weeks and were classified as British Thoracic Society (BTS) Steps 3–5, 
taking medium to high doses of inhaled steroids [20]. Participants were 
excluded if they were current or ex-smokers of greater than 20 pack 
years, had clinically significant cardio-pulmonary disease other than 
asthma, other significant co-morbidities uncontrolled with standard 
treatment, were on long-term anticoagulation, immune-modulators or 
interventional drug studies, had a bleeding diathesis, were alcohol or 
recreational drug abusers, were pregnant or had an abnormal chest 
X-ray or pulmonary imaging. The study was approved by the Berkshire 
Research Ethics Committee (reference 10/H0505/59). 
Lung function was assessed by spirometry, static and dynamic lung 
volumes and fractional exhaled nitric oxide (FeNO). Emphysema was 
excluded by gas transfer measurements in all ex-smokers. Skin prick 
tests to common aeroallergens were performed. The panel of allergens 
tested consisted of positive and negative controls, tree pollen, grass 
pollen, house dust mite, cat epithelia, dog and Aspergillus fumigatus. 
Blood tests in samples taken at baseline and exacerbation were per-
formed by the pathology services at PHT using commercial analysers 
and standard protocols and included full blood count, c-reactive protein 
(CRP), D-dimer (a marker of fibrin turnover), fibrinogen and IgE, INR 
and APTR. Plasma markers of platelet and endothelial activation 
(thrombin activatable fibrinolysis inhibitor (TAFI), plasminogen acti-
vator inhibitor-1 (PAI-1), platelet factor-4 (PF-4), transforming growth 
factor β1 (TGF-β1) and vascular endothelial growth factor (VEGF)) were 
analysed by enzyme-linked immunosorbent assay (ELISA). PAI-1, TGF- 
β1, VEGF and PF4 were analysed using ELISA kits from R&D Systems, 
and TAFI was measured using ELISA kits from Affinity Biologicals. 
Participants were prospectively followed up for the study period of 
11 months during which they recorded twice daily PEF measurements, 
kept a daily symptom diary (including SABA use) and collected thrice- 
weekly urine samples that were stored at home at 4 C for collection 
every 5–7 days for subsequent storage at -80 C prior to analysis. 
Participants contacted the research team on exacerbation for review, 
with baseline assessments repeated. This was repeated at four week 
intervals until self-reported recovery to baseline state or up to 8 weeks. 
Exacerbations met the ATS/ERS 2009 criteria [21] for a severe exacer-
bation (use of/increase in systemic corticosteroids, 40 mg oral pred-
nisolone once daily, for at least 3 days). Participants completed the study 
once recovered from exacerbation or at the end of the study period. 
2.2. Laboratory methods 
For FP-A analysis, protease inhibitors (Merck, UK) were added to 1 
ml urine samples and centrifuged at 5000 g for 10 min at 4 C. Cleared 
samples were passed through an Amicon Ultra-Concentrator centrifuge 
filter with 3 kDa cut off (Merck Millipore, UK) at 14,000 g for 60 min at 
4 C. The filtrate in the lower compartment (<3 kDa) was collected for 
FP-A (1500 Da) analysis. 1 ml of filtrate was added to a PD Miditrap G- 
10 (GE Healthcare) column equilibrated with deionised water and run 
into the bed. 0.7 ml water was run into the bed and any flow-through 
discarded. 1.5 ml water was added to the top of the column and the 
eluate collected and freeze-dried. 
The lyophilised sample was reconstituted in 150 μl UHQ water and 1 
μl of 3 mg/ml mouse anti-FPA [49D2] antibody (Abcam, UK). A stan-
dard curve was prepared using human FP-A (Sigma) in the concentration 
range 0–20 ng/ml in water and 1 μl of 3 mg/ml mouse anti-FPA [49D2] 
antibody added to 150 μl of each. Samples and standards were allowed 
to bind the antibody overnight at 4 C, to facilitate subsequent binding 
of the small (1500 Da) peptide to nitrocellulose membranes. 
Peptide-antibody complexes were bound to 0.2 μm nitrocellulose 
membrane (BioRad, UK) soaked in 20% methanol/PBS without Ca/Mg 
in a 96-well vacuum manifold (Jencons, UK). The samples, standards 
(150 μl) or blanks (20% methanol/PBS without Ca/Mg) were added and 
the fluid pulled through under vacuum. Proteins were fixed by baking 
the nitrocellulose membrane for 30 min at 100 C in a pre-heated oven. 
The membranes were stained for FP-A, with all steps at room tem-
perature, as follows. Membranes were blocked for 1 h in 100 ml of 2% 
Tween-20 and 5% skimmed-milk powder in PBS without Ca/Mg, then 
washed 5  5 minutes in 100 ml of 0.1% Tween-20 in PBS without Ca/ 
Mg. 
Membranes were incubated for 1 h with 5 ml per blot of sheep anti- 
FPA 1-16-HRP (Affinity Biologicals, Canada) diluted 1:10,000 (200 ng/ 
ml final concentration) in 2% Tween-20 and 5% skimmed milk in PBS 
without Ca/Mg. 
Membranes were washed 5  5 minutes in 100 ml of 0.1% Tween-20 
in PBS without Ca/Mg and HRP detected using West Pico Chemilumi-
nescent (Thermo Fisher, UK) solutions applied for 5 min. Excess solution 
was removed and luminescence captured using the Syngene G: Box using 
a series of 10  3 minute captures. 
2.3. Data analysis 
Cohort characteristics were described using median and interquartile 
ranges, or mean and standard deviations for normally distributed data. 
Paired data were compared using the paired t-test and Wilcoxon 
matched-pairs test for parametric and non-parametric data respectively. 
Changes in symptom score and reliever use were analysed by one-way 
ANOVA with Tukey’s multiple comparison test. Changes in urinary 
FP-A in relation to the time of exacerbation were analysed by one-way 
ANOVA with Dunn’s multiple comparisons test. Data from sub-group 
analysis of urinary FP-A to time to recovery was analysed using the 
Mann-Whitney unpaired t-test. The correlation between plasma IgE and 
urinary FP-A was analysed by Spearman rank correlation for non- 
normally distributed data. Statistical analyses were conducted using 
GraphPad Prism 8 (GraphPad Software Inc., USA). 
3. Results 
24 participants were recruited, of which 17 suffered an exacerbation 
during the study period (Fig. 1). 
Demographic data on participants is shown in Table 1. 
Of the 17 exacerbating patients, one participant was withdrawn due 
to a diagnosis of pneumonia at the first recovery visit, one participant 
was withdrawn due to a second exacerbation prior to the second re-
covery visit, and one had not recovered by the second recovery visit. 
Participants exacerbated at a median of 52 days (IQR 28–70.5) post- 
study entry. There were no significant differences between partici-
pants who exacerbated and did not exacerbate in terms of age, gender or 
asthma severity, however participants who exacerbated were signifi-
cantly more likely to have peripheral blood eosinophilia (400/μL) at 
baseline (p < 0.01). 
PEF values were compared between baseline (average for the first 
two weeks of measurement) and the average value for the 7-day period 
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prior to exacerbation; the mean (SD) baseline PEF was 304 (106) 
litres per minute, and this dropped to 281 (105) litres per minute in the 
week leading up to an exacerbation (p  0.01, n  16 (one patient had 
insufficient data recorded and was excluded from this analysis). PEFR 
variability did not increase significantly in the period prior to 
exacerbation. 
A symptom score from 0-4 was derived from the presence or absence 
of wheeze, night wakening, chest tightness and breathlessness during a 
24 h period. A significant (p < 0.05) increase in average symptom score 
was seen in the 7 days prior to exacerbation (2.33  0.86) compared to 
the 7 day average at baseline (1.43  1.01). A further significant (p <
0.01) increase in the symptom score was noted on the day of exacer-
bation (3.4  0.83). 
Reliever use, either number of puffs of SABA and/or number of SABA 
nebulisers in 24 h was also recorded. Reliever use was not significantly 
increased in the 7-day period prior to exacerbation (5.64  4.6) 
compared to the baseline 7-day average (4.31  4.9). Reliever use was 
increased significantly on the day of exacerbation (8.5  6.93) 
compared to both the baseline period (p < 0.01) and the 7-day period 
prior to exacerbation (p < 0.05). 
Plasma markers of fibrin turnover were assessed in samples collected 
at baseline and exacerbation, with the results shown in Table 2. 
This demonstrates a small, but statistically significant, increase in 
plasma D-dimer concentration at exacerbation, and a 46% reduction in 
TGFβ1 at exacerbation (both p  0.02). VEGF, PF4, fibrinogen, PAI-1 
and TAFI did not change significantly from baseline to exacerbation. 
INR and APTR at baseline were in the normal reference range (0.8–1.2) 
of both parameters, and there was no significant change in the INR or 
APTR at exacerbation. 
FP-A was analysed in urine samples collected in the 7 day periods 
before and after an exacerbation, and on the day of exacerbation (Fig. 2). 
The novel analytical approach to samples and standards is illustrated in 
Fig. 2A. Using this method, significantly higher peak FP-A concentration 
(0.395 (0.114–2.256) ng/ml) were detected 4.2  2 days prior to 
exacerbation (0.054 (0.022–0.765) ng/ml, p < 0.05) and the average 
value for the 7-day post exacerbation period (0.038 (0.007–0.174 ng/ 
ml, p < 0.0001) (Fig. 2B). Sub-group analysis (Fig. 2C) demonstrated 
significantly (p < 0.05) higher levels of urinary FP-A in the 5 patients 
that had not recovered within 4 weeks (2.866 (0.48–5.758) ng/ml) 
compared to those 9 patients that recovered within 4 weeks (0.189 
(0.0725–1.508) ng/ml). The patient that was re-admitted with a second 
exacerbation prior to the 8 week follow-up had the highest level of FP-A 
measured pre-exacerbation (9.41 ng/ml). 
Urinary FP-A concentrations (peak values or 7-day average values) 
did not correlate with PEF values, reliever use or symptom scores over 
the 7 day period prior to exacerbation. However, a significant (p < 0.01) 
negative correlation (Spearman rank correlation coefficient, r  -0.635) 
was noted between plasma IgE measured at baseline, and the peak 
Fig. 1. STROBE diagram of study participation.  
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urinary FP-A concentration detected in the 7 days prior to exacerbation 
(Fig. 2D). A similar significant (p < 0.05) negative correlation 
(Spearman rank correlation coefficient, r  -0.71) was also noted with 
plasma IgE at exacerbation. 
4. Discussion 
These data demonstrate significant activation of the coagulation 
system in moderate to severe asthmatics prior to an exacerbation. An 
increase in coagulation is supported by evidence of higher concentra-
tions of urinary FP-A, the first peptide cleaved from fibrinogen during 
thrombin-induced coagulation, in the 7 days leading up to an exacer-
bation relative to the week after the exacerbation. We propose this re-
flects coagulation in the airways, as indicated by our previous report of 
highly up-regulated fibrin formation in the airways of a patient with 
moderate asthma 5 days before a severe exacerbation requiring hospital 
admission [22]. FP-A is rapidly cleared by catabolism in the lung and the 
kidney, and urinary FP-A represents only a small fraction of that initially 
derived from cleavage of fibrinogen [23]. However, importantly, FP-A is 
the first urinary biomarker of coagulation to show promise in the pre-
diction of an exacerbation of asthma. Maximum levels of FP-A in urine 
were detected, on average, 4.2  2 days before exacerbation which of-
fers a substantial period of time for intervention prior to an increase in 
symptoms that might normally warrant an escalation in treatment. 
Exacerbations were defined per ATS/ERS 2009 criteria [21] as an 
increase in symptoms, sufficiently severe to warrant a course or an in-
crease in oral corticosteroid. The exacerbations were confirmed by re-
view with the study medical staff, and this is supported by the observed 
drop in PEF in the week leading up to exacerbation. However, the dif-
ferences in PEF between pre-exacerbation and exacerbation measure-
ments in our study were small, and are therefore useful objective 
markers of exacerbation but not clinically practicable to predict exac-
erbation in this study. 
Others have reported that a combination of symptom score (increase 
of more than two standard deviations) and PEF (decrease to <70% 
personal best) optimally predicted an asthma exacerbation a mean of 4.1 
days before occurrence [24]. It is interesting that we similarly detect a 
maximum increase in urinary FP-A at a mean of 4.2 days prior to 
exacerbation, which may therefore relate to increased pulmonary 
coagulation. In a large study of changes in PEF, symptom score and 
bronchodilator use over 14 days before and after an exacerbation, a 
relatively high level of false positive measures for PEF, symptom score 
and rescue treatment were reported outside the 28 day surrounding an 
exacerbation [25]. However, more work is needed to determine if 
changes in urinary FP-A will prove to be a more specific and sensitive 
test for predicting the onset of an asthma exacerbation. 
Nine of twenty-four participants did not complete the study, pri-
marily due to failure to exacerbate. This may be expected in an intensive 
study such as this due to improved medication compliance and the 
withdrawn participants were not significantly different to those who 
completed. Eosinophilia is a known marker for risk of exacerbation and 
that is demonstrated in this study. The relatively short time to exacer-
bation (median 52 days) in those who did exacerbate may reflect the 
predominantly female patient group [25] and their relative obesity 
which predisposes to early airway closure [26]. 
Changes in the balance of coagulation have previously been reported 
in peripheral blood and the airway in asthma. Previous work in our unit 
[10] has shown that moderate asthma is associated with a fibrinolytic 
intrabronchial environment which is corrected by inhaled steroid 
whereas severe asthma is associated with a pro-fibrinogenic, anti--
fibrinolytic, airway environment, despite high dose inhaled steroids. 
Patients with asthma are at increased risk of pulmonary embolism [27, 
28] which is associated with increased risk of asthma exacerbation [28], 
and impaired systemic fibrinolysis was specifically associated with risk 
of severe exacerbation [29]. 
Sneeboer et al. [30] investigated the impact of an exacerbation on 
the coagulation system by withdrawing inhaled steroids of 23 partici-
pants with moderate to moderately severe asthma, but they did not find 
significant changes in von Willebrand Factor (vWF), D-dimer, 
thrombin-antithrombin complex (TATc), plasminogen activator 
inhibitor-1 (PAI-1) or plasmin-antiplasmin complex(PAPc) in peripheral 
blood. In our study, we did not induce exacerbations, but rather fol-
lowed participants up until natural exacerbations occurred, and this may 
account for detection of significant changes in the plasma D-dimer 
marker of fibrin turnover. Manuyakorn et al. [16] followed a paediatric 
group from exacerbation to recovery and found increased vWF, PAI-1, 
and CRP during exacerbation and a positive correlation between 
D-dimer and exacerbation score, but not a significant difference between 
D-dimer at exacerbation and stable state. PAI-1 and CRP increased at 
exacerbation in our cohort but not significantly which may reflect dif-
ferences between adult and paediatric populations. 
Significantly lower levels of TGFβ in the circulation were previously 
reported in children with acute exacerbation of allergic asthma [31]. We 
also found significantly lower levels of plasma TGFβ1 at exacerbation. 
Table 1 
Participant demographics (N  24).  
Characteristic Mean (SD)/Median (Q1-Q3)/n 
(%) 
Age (years) 47.1 (12.6) 
BMI (kg/m2) 28 (25–33) 
Female gender 20 (83%) 
FEV1% Predicted 71.6% (19.7) 
FEV1/FVC ratio 0.66 (13.8) 
FeNO (ppb) 19.5 (13.8–39.5) 
Inhaled corticosteroid dose (BDP equivalents) 2000 (1150–2000) 
Oral corticosteroids 7 (29%) 
Montelukast (10 mg po, nocte) 12 (50%) 
Theophylline 10 (42%) 
Long acting β2-agonists 22 (92%) 
Peripheral eosinophil count (109/L) 0.3 (0.1–0.4) 
International normalised ratio (INR) 0.8 (0.8–0.9) 
Activated partial thomboplastin ratio (APTR) 1.0 (0.9–1.1) 
Exacerbations past 24 months 5.1 (3.1) 
BTS 2016 
classification 
Step 3 7 (29%) 
Step 4 9 (38%) 
Step 5 8 (33%) 
Atopic SPT positive 17 (71%) 
Raised IgE >81IU/ 
ml 
12 (50%) 
Smoking status Ex 83% 
Never 17%  
Table 2 
Plasma markers of fibrin turnover at baseline and exacerbation.  
Variable N Baseline median (Q1- 
Q3) or mean (SD) 
Exacerbation median 
(Q1-Q3) or mean 
(SD) 
P- 
value 
TAFI (ng/ml) 17 5406 (2591) 4764 (2030) 0.32 
PAI-1 (pg/ml) 17 15000 
(10336–30100) 
16200 (11400–37850) 0.33 
D-dimer 
(μgFEU/ml) 
14 0.21 (0.12–0.29) 0.25 (0.20–0.42) 0.02 
Fibrinogen (g/ 
l) 
13 3.08 (0.57) 3.21 (0.50) 0.40 
Platelets (109/ 
L) 
13 305 (61) 318 (64) 0.28 
PF4 (μg/ml) 17 3.9 (2.9) 2.6 (1.6) 0.12 
TGFβ1 (pg/ml) 17 1801 (721–2570) 966 (682–2376) 0.02 
VEGF (pg/ml) 17 23 (3–94) 20 (0–37) 0.22 
Eosinophils 
(109/L) 
13 0.30 (0.15–0.50) 0.30 (0.20–0.85) 0.28 
C-reactive 
protein (mg/ 
L) 
15 <5 (<5–7) 8 (4.25–12.5) 0.07 
INR 16 0.8 (0.8–0.8) 0.8 (0.8–0.9) 0.07 
APTR 16 1.0 (0.9–1.1) 1.0 (0.9–1.075) 0.86  
J.J. Owen et al.                                                                                                                                                                                                                                 
Respiratory Medicine: X 2 (2020) 100021
5
Since TGFβ1 is a potent inducer of PAI-1 expression we might have 
predicted significantly lower levels of plasma PAI-1. However, D-dimers 
also stimulate the release of biologically active PAI-1 from monocytes 
[32] and may contribute to the sustained levels of PAI-1. D-dimers and 
other fibrin(ogen) fragments are reported to modulate the inflammatory 
response [33], and may therefore be both markers of coagulation and 
mediators of inflammation. 
The urinary FP-A levels are significantly lower at exacerbation and 
afterwards than those detected prior to an exacerbation. This suggests 
that coagulation initiated in the airways prior to exacerbation is sub-
sequently limited, potentially by serpins acting under the control of 
glycosaminoglycans, including mast cell-derived heparin [34]. Howev-
er, anticoagulant protein C [35] and heparin [36] are relatively depleted 
in patients with asthma, supporting a pro-coagulant state. Factors that 
limit coagulation may therefore include tissue factor pathway inhibitor 
(TFPI) [37] or the endogenous thrombin inhibitor cartilage oligomeric 
matrix protein (COMP) [38], both major plasma and platelet derived 
inhibitors of thrombin. 
The significant negative correlation of urinary FP-A prior to exac-
erbation with plasma IgE concentrations suggest an IgE-mediated anti-
coagulation mechanism. This might reflect IgE-dependent mast cell 
activation and release of heparin or tryptase, which cleaves fibrinogen α 
and β-chains and renders it unclottable by thrombin [39]. Alternatively, 
IgE-dependent recruitment and activation of platelets in the airways 
contributes to many of the characteristic features of asthma, including 
bronchial hyperresponsiveness, bronchoconstriction, airway inflamma-
tion and airway remodelling [40]. However, the role of platelets in 
promoting pulmonary coagulation and/or IgE-dependent regulatory 
pathways to limit fibrin formation needs further investigation. 
Bazan-Socha et al. [41] previously reported increased endogenous 
thrombin potential (ETP) and impaired fibrinolysis (prolonged clot lysis 
time) in asthma patients compared to healthy controls. They further 
reported no significant difference in ETP between individuals with 
allergic asthma and non-allergic asthma, although defective fibrinolysis, 
measured as a significantly longer clot lysis time, was reported in pa-
tients with non-allergic compared to allergic asthma [41]. However, a 
correlation with IgE was not reported. The same study also found that 
montelukast therapy, but not systemic corticosteroid therapy, in 
asthmatics was associated with significantly increased endogenous 
thrombin potential (ETP), an indicator of a pro-
thrombotic/hypercoagulable state, as well as an increased clot lysis 
time. Half of our study participants were receiving montelukast as part 
of their standard therapy, but we found no significant difference (p 
0.86) in the subgroup analysis of urinary FP-A prior to exacerbation in 
those receiving montelukast therapy and those who were not. 
Overall, our study explored the feasibility of detecting FP-A, a 
marker of coagulation, in urine before, during and after an exacerbation 
of asthma using a novel immunodetection method. A limitation of the 
study is that the results are from a small, but well characterised, mostly 
severe, predominantly female, Caucasian cohort with high BMI, pre-
disposed to hypercoagulation [41], and need to be validated in other 
populations. Current smokers were excluded as cigarette smoking is 
known to affect the balance of the coagulation cascade [42–44], and so 
these results may not apply to people with asthma who smoke. 
Triggers of the asthma attack were not identified in our study, but are 
likely to be viral infections and associated factors such as airway bac-
teria [45] and allergens [6]. It is estimated that up to 85% of asthma 
exacerbations in children and up to 80% in adults are linked to viral 
infections [45]. Viral infection [12] and allergen exposure [13] have 
been shown to promote pulmonary fibrin formation. Coagulation is 
believed to play a role in clearance and control of infectious agents [46] 
and, in a mouse model, fibrinopeptide B was recently identified as a 
potential serum marker of RSV infection [47]. 
This is the only study to date examining markers of coagulation in 
urine in acute exacerbation of asthma. A further prospective study is 
required to confirm the utility of the specific marker of coagulation, 
urinary FP-A, as a predictive biomarker of exacerbation, in the hope 
that, through escalation of treatment, it may change the natural course 
of the disease, and in particular the accelerated decline in lung function 
associated with exacerbation of asthma [48,49]. Others have reported 
that urinary bromotyrosine, measured by stable isotope dilution 
high-performance liquid chromatography with on-line electrospray 
ionisation tandem mass spectrometry, predicts asthma exacerbations in 
children [50]. However, detecting FP-A in urine presents the realistic 
prospect of translating these findings into a practical and acceptable 
point-of-care test, such as a lateral flow (dip-stick) test for patients with 
Fig. 2. Urinary FP-A analysis by 
immunoblot. 
A; A representative immunoblot 
showing the FP-A standard curve and a 
set of urine samples collected from a 
patient before and after an exacerba-
tion, indicated by the blue arrow. Blots 
were analysed by scanning densitom-
etry using Quantiscan software. 
B; FP-A concentration (median and 
interquartile range, n  17) in urine in 
the 7-day period before and after an 
exacerbation of asthma. The data shows 
the highest value detected in urine 
before an exacerbation which on 
average was 4.2  2 days prior to an 
exacerbation, and the average concen-
trations on the day of exacerbation and 
in the 7 days afterwards. 
C; FP-A concentration (median and 
interquartile range) in urine in the 7- 
day period before an exacerbation in 
relation to time to recovery by one 
month (n  9) and by 2 months (n  5). 
D; Plasma IgE at baseline in relation to 
the highest value of urinary FP-A 
detected in the 7-day period prior to 
exacerbation (n  17).   
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